Formycon AG: management transactions · Germany · BaFin

About Formycon AG

Formycon AG is a German biosimilars specialist listed on Xetra/Frankfurt (DAX/MDAX/SDAX), headquartered in Planegg-Martinsried near Munich, Germany. The company positions itself as an independent developer of high-quality biosimilars, i.e. follow-on biologic medicines designed to provide patients and healthcare systems with more affordable alternatives to already marketed reference biologics. Its business model is based on identifying biologic molecules with strong commercial potential, executing preclinical and clinical development, obtaining regulatory approvals, and monetizing assets through licensing and commercialization partnerships with international pharma companies. ([formycon.com](https://www.formycon.com/en/company/about-us/?utm_source=openai)) Formycon was built at the intersection of the biosimilars industry’s emergence and the need for specialized development expertise. Over time, it has assembled a team with deep scientific, clinical, manufacturing-process, and regulatory know-how, including professionals who helped bring some of the world’s first biosimilars to market. The company’s platform is focused on comparability analytics, process development, and clinical execution. Its pipeline includes FYB201 (ranibizumab, a biosimilar candidate to Lucentis®), FYB203 (aflibercept, a biosimilar candidate to Eylea®), FYB202 (ustekinumab, a biosimilar candidate to Stelara®), and FYB206 (pembrolizumab, a biosimilar candidate to Keytruda®). Additional earlier-stage programs extend the optionality of the portfolio. ([formycon.com](https://www.formycon.com/en/pipeline/?utm_source=openai)) In competitive terms, Formycon operates in a demanding global market populated by large pharma companies, biosimilar/generic specialists, and powerful commercialization partners. Its differentiation lies in its regulatory and clinical execution capabilities, its ability to secure global partnerships, and its exposure to several large therapeutic franchises, particularly ophthalmology, immunology, and oncology. At the same time, the company is exposed to the usual biosimilar-sector risks: pricing pressure, intense competition, regulatory timing, manufacturing complexity, and reliance on partners for market access and launch execution. ([formycon.com](https://www.formycon.com/en/company/about-us/?utm_source=openai)) Recent highlights show continued portfolio maturation and commercialization progress. In 2025, FYB202/Otulfi® received interchangeable biosimilar status in the United States, while FYB203/AHZANTIVE® advanced through approvals and commercialization agreements, including in Europe and North America. In February 2025, Formycon decided to discontinue the Phase III Lotus trial for FYB206 after positive FDA feedback on the comparability strategy, favoring an analytical package supported by an ongoing Phase I PK study. More recently, the company published preliminary 2025 figures and indicated revenue momentum supported by upfront payments linked to FYB206 and disciplined cost control. ([formycon.com](https://www.formycon.com/blog/press-release/formycon-und-fresenius-kabi-geben-fda-zulassung-von-fyb202-otulfi-ustekinumab-aauz-als-austauschbares-biosimilar-interchangeable-bekannt/?utm_source=openai)) For investors, Formycon is best viewed as a specialty growth story at the intersection of science, regulation, and partnering, with valuation and execution closely tied to pipeline success and commercialization progress across the U.S., Europe, and other international markets.